ALLO Allogene Therapeutics, Inc.
Price Chart
Executive Summary
Allogene Therapeutics announced regulatory clearance to expand its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia, following a positive interim futility analysis showing 58.3% MRD clearance in the cema-cel arm versus 16.7% in standard of care. The trial expansion supports global development, with enrollment expected to reach ~220 patients by end-2027 and an interim event-free survival analysis anticipated in mid-2027.
Actionable Insight
The strong MRD clearance data and clean safety profile de-risk the ALPHA3 trial and support confidence in cema-cel’s potential as a first-line consolidation therapy. With no serious adverse events and outpatient feasibility, this positions Allogene favorably ahead of the mid-2027 interim analysis — a key catalyst. Monitor site activation timelines and enrollment progress in new geographies.
Key Facts
- Regulatory authorities in South Korea and Australia have cleared expansion of the ALPHA3 Phase 2 trial for cema-cel in first-line LBCL.
- Interim futility analysis in 24 patients showed 58.3% MRD clearance with cema-cel vs. 16.7% in standard of care.
- No serious treatment-related adverse events, CRS, or ICANS were reported; no hospitalizations occurred.
- Trial expected to enroll ~220 patients globally by end of 2027, with interim EFS analysis in mid-2027 and primary analysis in mid-2028.
- Cema-cel has RMAT designation in r/r LBCL and is being studied as a potential '7th cycle' consolidation therapy post-R-CHOP.
Financial Impact
Non-immediate financial impact; potential long-term value creation if trial success leads to BLA submission and approval.
Risk Factors
- Interim data from only 24 patients may not predict final outcomes.
- MRD clearance is a surrogate endpoint; it may not translate into improved event-free or overall survival.
- Future trial execution risks in new jurisdictions could delay enrollment.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
DEFA14A
| $2.17 $1.88 | ▼ −13.36% | ▼ −10.84% | $1.82 (−16.13%) |
|
May 28, 2026
12d ago
|
8-K
| $2.17 $1.88 | ▼ −13.36% | ▼ −10.84% | $1.82 (−16.13%) |
|
May 28, 2026
12d ago
|
Press Release
| $2.17 $2.00 | ▼ −7.83% | ▼ −7.54% | $1.82 (−16.13%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $2.32 $2.19 | ▼ −5.60% | ▼ −6.69% | $1.82 (−21.55%) |
|
Apr 15, 2026
7w ago
|
8-K
| $2.37 $2.35 | ▼ −0.84% | ▼ −1.83% | $1.82 (−23.21%) |
|
Apr 15, 2026
7w ago
|
424B5
| $2.37 $2.35 | ▲ +0.84% | ▲ +1.83% | $1.82 (+23.21%) |
|
Apr 15, 2026
7w ago
|
Press Release
| $2.17 $2.39 | ▲ +10.14% | ▲ +8.50% | $1.82 (−16.13%) |
|
Apr 15, 2026
8w ago
|
Press Release
| $2.17 $2.39 | ▼ −10.14% | ▼ −8.50% | $1.82 (+16.13%) |
|
Apr 13, 2026
8w ago
|
424B5
| $2.28 $2.32 | ▲ +1.75% | ▲ +0.36% | $1.82 (−20.18%) |
|
Apr 13, 2026
8w ago
|
8-K
| $2.28 $2.32 | ▼ −1.75% | ▼ −0.36% | $1.82 (+20.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access